[Skip to Content]
[Skip to Content Landing]
October 10, 1977

Combination Chemotherapy With Doxorubicin and Lomustine: Treatment of Refractory Hodgkin's Disease

JAMA. 1977;238(15):1659-1661. doi:10.1001/jama.1977.03280160053028

Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine. Toxicity was acceptable. Five patients (50%) attained complete remission (median duration, 15 months). Three patients attained a partial remission (median duration, four months). Survival ranged from three to more than 40 months, and five patients are still alive. One patient remains disease-free after a course of radiation therapy to a site of localized nodal relapse. The doxorubicin-lomustine regimen has induced meaningful remissions in a patient population with very refractory disease.

(JAMA 238:1659-1661, 1977)